Market Overview

Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients With Myasthenia Gravis; Says Both Doses of Tirasemtiv Were Well Tolerated

Share:

Posted-In: News

 

Related Articles (CYTK)